עברית
Creativity Value, PR agency in Israel

Health-Tech and Life Sciences PR in Israel: A Guide for Companies, Investors and International Entrants

Health-tech and life sciences companies communicate under rules that other technology companies never meet. A claim about a product is also a claim about patients. A press release can move a share price or draw the attention of a regulator. And the audience includes doctors, hospital managers, insurers and investors, each of whom reads the same announcement differently.

This guide covers the Israeli sector in numbers, the rules that shape what can be said, and a practical plan for building a reputation, both for Israeli companies and for international health companies entering Israel.

In short

  • Israel has about 1,800 active life sciences companies employing about 81,000 people.
  • Private investment in 2025 fell to its lowest level in five years, so every announcement has to work harder.
  • In health, evidence is the story. Publish data, not adjectives.
  • Clinical, regulatory and commercial milestones each need a different message and a different outlet.
About 1,800
active life sciences companies in Israel
About 81,000
people employed in the sector
About $1.6B
invested in Israeli life sciences companies in 2025
$352M
raised by Israeli mental health technology companies in 2025, up 150%

The sector in numbers

The annual report by the Israel Advanced Technology Industries association, the Israel Innovation Authority and PwC Israel describes a stable but under-funded sector. The number of active companies held steady, exports were unchanged, and large acquisitions continued, while private fundraising fell to a five-year low.

Indicator2025Note
Active companiesAbout 1,800Stable in recent years
EmployeesAbout 81,000Biomed is about 30% of companies and over half the workforce
Total investmentAbout $1.6 billionMore than 90% from private investment
Pharmaceutical exportsAbout $1.7 billionSimilar to 2024
Medical equipment exportsAbout $3.3 billionSimilar to 2024
Large acquisitionsAt least one above $500 millionSixth year in a row
Mental health technology funding in Israel (in $ millions)

2024$138M
2025$352M
Mental Health Innovation Map 2026, Startup Nation Central and partners.

For communications the conclusion is practical. When money is scarce, investors and partners look harder at credibility. Companies that have built a record of accurate, evidence-based announcements find it easier to raise funds and sign partners than those that appear in the press only when they need something.

What makes health PR different

AreaSoftware companyHealth-tech or life sciences company
ClaimsPerformance and savingsClinical outcomes, which must be supported by data
RegulationLimitedHealth ministry, FDA, CE marking, advertising rules for medical products
ProofCustomer logosTrials, peer-reviewed publications, regulatory clearances
SpokespeopleFounderFounder plus a clinician or scientist
TimelineMonthsYears, with long quiet periods between milestones
RiskDisappointing a customerMisleading patients, regulators or investors

Milestones that make news

MilestoneBest audienceWhat to include
Funding roundBusiness and tech mediaAmount, investors, what the money will fund, stage of development
Trial resultsMedical and science mediaStudy design, number of participants, endpoints, limitations
Regulatory clearanceTrade, business and medical mediaWhat exactly was cleared, for which use, in which market
Hospital or health fund partnershipLocal business and health mediaScope, sites, what will be measured
Peer-reviewed publicationScience media and professional audiencesJournal, authors, main finding in plain language
Commercial launchTrade and local mediaAvailability, price or reimbursement where relevant

The rules of careful language

  • Say what the study showed, not what you hope the product will do.
  • Give the number of participants and the stage of the trial.
  • Separate cleared uses from uses still under investigation.
  • Avoid words such as cure, breakthrough and revolutionary unless an independent authority has used them.
  • Have every release reviewed by the medical and regulatory leads, and by legal counsel if the company is listed.
  • Never use patient stories without written consent and a clear explanation of how they will be published.

A plan for the quiet periods

Between milestones a health company may have nothing to announce for a year or more. This is when reputations are built or lost. The tools are different from news announcements.

STEP 1
Expert voice
Opinion articles and commentary by the founder or chief medical officer on the disease area.
STEP 2
Data
Publish market or clinical insight that journalists can use.
STEP 3
Conferences
Speak at medical and industry events and report from them.
STEP 4
Partners
Joint stories with hospitals, universities and patient groups.
STEP 5
Podcasts
Long-form interviews that explain complex science.

International health companies entering Israel

Israel is attractive for health companies because of its digitised health records, four national health funds and concentrated hospital system. For a company arriving from abroad, the first communications questions are local: which health fund or hospital is the partner, what will Israeli patients gain, and who speaks for the company in Hebrew. A local partner named in the announcement is the strongest signal of commitment. Our playbook for entering the Israeli market and the page on PR in Israel for international companies cover the wider process.

Related guides: the Israeli media landscape, how to announce a funding round and PR for AI visibility.

Our service: Health-tech and life sciences PR agency in Israel

Frequently asked questions

Can we announce early trial results?

Yes, if the announcement states clearly the stage of the trial, the number of participants and the limits of the findings. Overstating early data damages credibility with journalists, investors and regulators.

Who should speak for a health company?

The founder for the business story and a clinician or scientist for the medical story. Journalists covering health expect to speak to someone who can answer clinical questions.

Is it harder to get coverage in a weak funding market?

Funding news is rarer, so companies need other stories: data, partnerships, expert commentary and clinical milestones.

Do we need separate Hebrew and English communications?

Usually yes. Israeli media and the health system respond to local partners and local benefit, while international media look for market size, evidence and regulatory status.

How do regulatory rules affect a press release?

Claims about a medical product must match what the regulator has cleared. Uses under investigation must be described as such.

Planning PR in Israel?

Creativity Value is a local PR agency for startups and international companies entering the Israeli market.

Talk to us